Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 1.97 and has seen 1.78 million shares traded in the last trading session. The company, currently valued at $178.84M, closed the last trade at $3.74 per share which meant it gained $0.54 on the day or 16.69% during that session. The CRDF stock price is -71.66% off its 52-week high price of $6.42 and 74.87% above the 52-week low of $0.94. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.83 million shares traded. The 3-month trading volume is 549.18K shares.
The consensus among analysts is that Cardiff Oncology Inc (CRDF) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.27.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Sporting 16.69% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CRDF stock price touched $3.74 or saw a rise of 1.32%. Year-to-date, Cardiff Oncology Inc shares have moved 152.70%, while the 5-day performance has seen it change 25.08%. Over the past 30 days, the shares of Cardiff Oncology Inc (NASDAQ:CRDF) have changed 43.85%. Short interest in the company has seen 7.32 million shares shorted with days to cover at 13.38.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Figures show that Cardiff Oncology Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 8.09% over the past 6 months, with this year growth rate of -8.60%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 8.60%.
5 analysts offering their estimates for the company have set an average revenue estimate of 80k for the current quarter. 5 have an estimated revenue figure of 80k for the next ending quarter. Year-ago sales stood 141k and 156k respectively for this quarter and the next, and analysts expect sales will shrink by -43.30% for the current quarter and 8.60% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 35.42% over the past 5 years.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Insiders own 7.25% of the company shares, while shares held by institutions stand at 27.26% with a share float percentage of 29.39%. Investors are also buoyed by the number of investors in a company, with Cardiff Oncology Inc having a total of 122.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 2.63 million shares worth more than $5.84 million. As of 2024-06-30, BLACKROCK INC. held 5.883% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 2.14 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.74 million and represent 4.7816% of shares outstanding.
